Continuous epoprostenol therapy and septal defect closure in a patient with severe pulmonary hypertension

Catheterization and Cardiovascular Interventions

Volumn 73, Issue 5, 2009, Pages 688-691

  Hirabayashi, Aki ^a   Miyaji, Katsumasa ^a   Akagi, Teiji ^b  

^a NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Heart catheterization; Therapeutics; Vascular resistance; Vasodilation

Indexed keywords

BERAPROST; PROSTACYCLIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CLIP; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FUNCTIONAL STATUS; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HEART DILATATION; HEART LEFT RIGHT SHUNT; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG VASCULAR RESISTANCE; OXYGEN THERAPY; PERCUTANEOUS CORONARY INTERVENTION; PULMONARY HYPERTENSION; TRANSCATHETER CLOSURE; TREATMENT RESPONSE; TRICUSPID VALVE REGURGITATION;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; ECHOCARDIOGRAPHY, DOPPLER, COLOR; ELECTROCARDIOGRAPHY; EPOPROSTENOL; FEMALE; HEART CATHETERIZATION; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; HYPERTENSION, PULMONARY; INJECTIONS, INTRAVENOUS; OXYGEN INHALATION THERAPY; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 65549157641     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21877     Document Type: Article

References (5)

1. Webb G, Gatzoulis MA. Atrial septal defects in the adult: Recentprogress and overview. Circulation 2006;114:1645-1653.
2. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-1928.
3. Puri A, McGoon MD, Kushwaha SS. Pulmonary arterial hypertension: Current therapeutic strategies. Nat Clin Pract Cardiovasc Med 2007;4:319-329.
4. Frost AE, Quinones MA, Zoghbi WA, Noon GP. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant 2005;24:501-503.
5. Schwerzmann M, Zafar M, McLaughlin PR, Chamberlain DW, Webb G, Granton J. Atrial septal defect closure in a patient with "irreversible" pulmonary hypertensive arteriopathy. Int J Cardiol 2006;110:104-107.